BP
RDY icon

Ballentine Partners’s Dr. Reddy's Laboratories RDY Stock Holding History

Ballentine Partners’s Portfolio RDY Stock Details RDY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.56M Buy
107,479
+2,591
+2% +$35K 0.02% 273
2026
Q1 		$1.45M Buy
104,888
+435
+0.4% +$6.06K 0.02% 268
2025
Q4 		$1.47M Sell
104,453
-27,709
-21% -$389K 0.02% 247
2025
Q3 		$1.85M Sell
132,162
-13,056
-9% -$188K 0.03% 207
2025
Q2 		$2.18M Buy
145,218
+70,110
+93% +$1M 0.03% 179
2025
Q1 		$991K Sell
75,108
-29,607
-28% -$409K 0.02% 295
2024
Q4 		$1.65M Buy
104,715
+27,455
+36% +$412K 0.03% 208
2024
Q3 		$1.23M Buy
77,260
+11,195
+17% +$180K 0.02% 245
2024
Q2 		$1.01M Sell
66,065
-890
-1% -$12.8K 0.02% 261
2024
Q1 		$982K Buy
66,955
+13,330
+25% +$195K 0.02% 256
2023
Q4 		$746K Buy
53,625
+19,500
+57% +$261K 0.02% 280
2023
Q3 		$456K Buy
34,125
+1,875
+6% +$25.4K 0.01% 339
2023
Q2 		$407K Buy
+32,250
New +$376K 0.01% 366

Other funds holding RDY

Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
AIM
Aikya Investment Management London, United Kingdom $341M AUM 28.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Ballentine Partners's RDY Position: Q2 2026 in Review

Ballentine Partners increased its Dr. Reddy's Laboratories (RDY) stake by 2.5% in Q2 2026, buying an estimated $35K and bringing the position to 107,479 shares worth $1.56M. The position accounts for 0.02% of the portfolio, ranked #273.

Ballentine Partners first reported a position in RDY in Q2 2023 and has held it in 13 quarters since. The position peaked at $2.18M in Q2 2025. 239 funds tracked by Wall St. Rank hold RDY as of Q2 2026.

  • Ballentine Partners held 107,479 shares of Dr. Reddy's Laboratories worth $1.56M as of Q2 2026.
  • Ballentine Partners bought 2,591 Dr. Reddy's Laboratories shares in Q2 2026, an estimated $35K.
  • Dr. Reddy's Laboratories made up 0.02% of Ballentine Partners's portfolio in Q2 2026, its #273 holding.
  • Ballentine Partners first reported a position in Dr. Reddy's Laboratories in Q2 2023 and has held it in 13 quarters since.
  • Ballentine Partners's Dr. Reddy's Laboratories position peaked at $2.18M in Q2 2025.
  • 239 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q2 2026.

Based on Ballentine Partners's 13F filing for Q2 2026, filed 17 Jul 2026.